Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Conflicting reports of injuries after malfunction halts Wheaton fireworks display
Wheaton’s annual Independence Day fireworks display came to an abrupt and unexpected halt Wednesday night when... -
Daily Herald opinion: On Independence Day, we celebrate our nation’s birth and recommit to its future
Editor's Note: The editorial below is an updated version of one first published on July 4,... -
Cubs lose again, but Imanaga made his case for all-star nod
Somebody has to represent the #Cubs in the All-Star Game. Pitcher Shota Imanaga made his case...